IP Verse

Combination Therapy For Copd - EP3500241

The patent EP3500241 was granted to Chiesi Farmaceutici on Oct 4, 2023. The application was originally filed on Aug 17, 2017 under application number EP17758473A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3500241

CHIESI FARMACEUTICI
Application Number
EP17758473A
Filing Date
Aug 17, 2017
Status
Granted And Under Opposition
Sep 1, 2023
Grant Date
Oct 4, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ELKINGTON AND FIFEJul 4, 2024ELKINGTON AND FIFEADMISSIBLE
BOTTI & FERRARIJul 3, 2024BOTTI & FERRARIADMISSIBLE
HASELTINE LAKE KEMPNERJul 3, 2024-ADMISSIBLE

Patent Citations (25) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP1157689
DESCRIPTIONUS2011150782
DESCRIPTIONUS2015182450
DESCRIPTIONUS2015182459
DESCRIPTIONUS2956062
DESCRIPTIONWO0149350
DESCRIPTIONWO0176575
DESCRIPTIONWO03053501
DESCRIPTIONWO2005074918
DESCRIPTIONWO2005107873
DESCRIPTIONWO2005110402
DESCRIPTIONWO2006105401
DESCRIPTIONWO2007057219
DESCRIPTIONWO2007057221
DESCRIPTIONWO2007057222
DESCRIPTIONWO2007057223
INTERNATIONAL-SEARCH-REPORTUS2015150787
INTERNATIONAL-SEARCH-REPORTUS2015182459
INTERNATIONAL-SEARCH-REPORTWO2014033057
OPPOSITIONUS10098837
OPPOSITIONUS2015150787
OPPOSITIONUS2015182459
OPPOSITIONWO2011076843
OPPOSITIONWO2014033057
OPPOSITIONWO2018033598

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- Singh D, "Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation", European respiratory journal, (20190518), URL: https://erj.ersjournals.com/content/erj/53/5/1900235.full.pdf, (20210430), XP055800541-
OPPOSITION- Anonymous, "Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease", ClinicalTrials.gov History of Changes for Study: NCT01911364, (20160405), ClinicalTrials.gov History of Changes for Study: NCT01911364, XP093197425-
OPPOSITION- "Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease", ClinicalTrials.gov History of Changes for Study: NCT01911364, (20160405), ClinicalTrials.gov History of Changes for Study: NCT01911364, XP093197425-
OPPOSITION- Hurst John R, Vestbo Jørgen, Anzueto Antonio, Locantore Nicholas, Müllerova Hana, Tal-Singer Ruth, Miller Bruce, Lomas David A, Agusti Alvar, Macnee William, Calverley Peter, Rennard Stephen, Wouters F M, Wedzicha Jadwiga A, "Susceptibility to exacerbation in chronic obstructive pulmonary disease", The New England Journal of Medicine, (20100101), vol. 363, pages 1128 - 1138, XP093197419-
OPPOSITION- Singh D, "Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation", European respiratory journal, (2019), vol. 53, XP055800541-
OPPOSITION- SWEETMAN S.C. (ED.)., MARTINDALE : THE COMPLETE DRUG REFERENCE, 33rd edition, GB , LONDON : PHARMACEUTICAL PRESS. , (20020101), page 467, 027800, ISBN 978-0-85369-499-1, XP002579323-
OPPOSITION- Taylor Glyn, Warren Simon, Tran Cuong H, "Next Generation Formulations for pMDIs", Drug Delivery to the Lungs, (20160101), vol. 27, XP093200131-
OPPOSITION- Vestbo J, Papi A, Corradi M Et Al., "Supplement to: Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial", Lancet, (20161108), pages 1 - 21, XP093197433-
OPPOSITION- Singh Dave; Schroder-Babo Winfried; Cohuet Geraldine; Muraro Annamaria; Bonnet-Gonod Francoise; Petruzzelli Stefano; Hoffmann Martin; Siergiejko Zenon, "The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study)", Respiratory Medicine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20160326), vol. 114, doi:10.1016/j.rmed.2016.03.018, ISSN 0954-6111, pages 84 - 90, XP029518719
OPPOSITION- Vestbo Jorgen; Papi Alberto; Corradi Massimo; Blazhko Viktor; Montagna Isabella; Francisco Catherine; Cohuet Geraldine; Vezzoli Stefano; Scuri Mario; Singh Dave, "Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20170403), vol. 389, no. 10082, doi:10.1016/S0140-6736(17)30188-5, ISSN 0140-6736, pages 1919 - 1929, XP085018828
OPPOSITION- Vestbo Jorgen; Papi Alberto; Corradi Massimo; Blazhko Viktor; Montagna Isabella; Francisco Catherine; Cohuet Géraldine; Vezzoli Stefano; Scuri Mario; Singh Dave, "Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20170403), vol. 389, no. 10082, doi:10.1016/S0140-6736(17)30188-5, ISSN 0140-6736, pages 1919 - 1929, XP085018828
OPPOSITION- Sykes David A., Dowling Mark R., Leighton-Davies Juliet, Kent Toby C., Fawcett Lindsay, Renard Emilie, Trifilieff Alexandre, Charlton Steven J., "The Influence of Receptor Kinetics on the Onset and Duration of Action and the Therapeutic Index of NVA237 and Tiotropium", Journal of pharmacology and experimental therapeutics, American Society for Pharmacology and Experimental Therapeutics, US, US , (20121101), vol. 343, no. 2, doi:10.1124/jpet.112.194456, ISSN 0022-3565, pages 520 - 528, XP093200140
OPPOSITION- O'donnell D E, Parker C M, "COPD exacerbations 3: Pathophysiology", Thorax, (20060101), vol. 61, doi:10.1136/thx.2005.041830, pages 354 - 361, XP093197386
OPPOSITION- Kerwin Edward, Hebert Jacques, Gallagher Nicola, Martin Carmen, Overend Tim, Alagappan Vijay K T, Lu Yimeng, Banerji Donald, "Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study", EUROPEAN RESPIRATORY JOURNAL, European Respiratory Society, GB, GB , (20120726), vol. 40, no. 5, doi:10.1183/09031936.00040712, ISSN 0903-1936, pages 1106 - 1114, XP093197415
OPPOSITION- Haughney John, Gruffydd-Jones Kevin, Roberts June, Lee Amanda J, Hardwell Alison, Mcgarvey Lorcan, "The distribution of COPD in UK general practice using the new GOLD classification", European Respiratory Journal, (20140101), vol. 43, doi:10.1183/09031936.00065013, pages 993 - 1002, XP093197411

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents